Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.
Cancer Immunol Immunother
; 64(3): 311-23, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25403749
ABSTRACT
The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8(+) T lymphocytes that efficiently prevent tumor development. However, the therapeutic effect of such a vaccine is limited. We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8(+) T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate. As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Melanoma Experimental
/
Linfócitos T CD8-Positivos
/
Vacinas Anticâncer
/
Antígeno CTLA-4
/
Imunoterapia
/
Proteínas de Membrana
/
Antígenos de Neoplasias
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article